Cipla receives USFDA nod for manufacturing generic version of Brovana
Cipla Ltd, a leading pharmaceutical company, announced today that it has received a go-ahead from USFDA for its abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution of strength 15 mcg/2 ml.
USFDA approved Arformoterol Tartrate inhalation solution is a generic therapeutic equivalent version of Brovana, which is manufactured by the US-based Sunovion Pharmaceuticals Inc.
Arformoterol is a bronchodilator belonging to the class of drugs known as long-acting beta-agonists (LABAs). It is directed to be taken twice daily by patients undergoing the treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema. It is used as a long-term (maintenance) treatment to prevent and help reduce wheezing & shortness of breath caused by breathing problems.
As per the estimates of IQVIA (IMS Health), Brovana had sales of approximately USD 438 million for the 1-year period ending April 2021 in the US market.
At 11.55 am, the share price of Cipla Ltd was trading at Rs 960, which was an increase of 0.46 per cent over its previous day’s closing price of Rs 955.65 on BSE.